ATE420946T1 - Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine - Google Patents

Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine

Info

Publication number
ATE420946T1
ATE420946T1 AT04715780T AT04715780T ATE420946T1 AT E420946 T1 ATE420946 T1 AT E420946T1 AT 04715780 T AT04715780 T AT 04715780T AT 04715780 T AT04715780 T AT 04715780T AT E420946 T1 ATE420946 T1 AT E420946T1
Authority
AT
Austria
Prior art keywords
cells
csf
monocytes
dendritic
dendritic cells
Prior art date
Application number
AT04715780T
Other languages
English (en)
Inventor
Benjamin A Tjoa
Marnix Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of ATE420946T1 publication Critical patent/ATE420946T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT04715780T 2003-02-27 2004-02-27 Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine ATE420946T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45101503P 2003-02-27 2003-02-27

Publications (1)

Publication Number Publication Date
ATE420946T1 true ATE420946T1 (de) 2009-01-15

Family

ID=32927693

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715780T ATE420946T1 (de) 2003-02-27 2004-02-27 Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine

Country Status (20)

Country Link
US (4) US8389278B2 (de)
EP (1) EP1604016B1 (de)
JP (1) JP4762887B2 (de)
KR (2) KR101201875B1 (de)
CN (1) CN1784488B (de)
AT (1) ATE420946T1 (de)
AU (2) AU2004214896A1 (de)
BR (1) BRPI0407900A (de)
CA (1) CA2517295C (de)
CY (1) CY1109099T1 (de)
DE (1) DE602004019057D1 (de)
DK (1) DK1604016T3 (de)
ES (1) ES2321939T3 (de)
IL (1) IL170512A (de)
MX (1) MXPA05009178A (de)
NZ (1) NZ542071A (de)
PL (1) PL209998B1 (de)
RU (1) RU2364625C2 (de)
TW (1) TW200506061A (de)
WO (1) WO2004076651A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
CN1738619B (zh) * 2002-12-06 2012-04-18 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤的制药用途
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用
EP1676132B1 (de) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Kombination von Chemotherapie und Applikation von Glioma-Antigen-gepulsten dendritischen Zellen zur Glioma Behandlung
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
AU2006249640C1 (en) 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
EP1957634A4 (de) * 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc Zusammensetzungen und verfahren zur induzierung der aktivierung unreifer monozytischer dendritenzellen
EP1806395A1 (de) * 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation von dendritischen Zellen
CA2700573C (en) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
EP1920781B1 (de) * 2006-11-10 2015-03-04 Glycotope GmbH Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren
KR100896747B1 (ko) 2007-05-30 2009-05-11 동아대학교 산학협력단 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
DK2328923T3 (en) * 2008-09-02 2016-03-21 Cedars Sinai Medical Center CD133 epitopes
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
FR2940451B1 (fr) * 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
ES2618573T3 (es) * 2009-05-07 2017-06-21 ImmunoCellular Therapeutics,Ltd Epítopos de CD133
KR101911380B1 (ko) * 2009-07-24 2018-10-25 로드아일랜드하스피틀 아스파라기닐-β-히드록실라제 발현 종양을 위한 수지상 세포 백신
WO2011046832A2 (en) * 2009-10-12 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Granulysin in immunotherapy
AU2011227447B2 (en) * 2010-03-15 2016-04-14 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
RU2458985C1 (ru) * 2011-03-18 2012-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
SG11201404570WA (en) * 2012-02-10 2014-11-27 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
CN104098652B (zh) * 2014-07-23 2016-11-09 国家纳米科学中心 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用
DK3173420T3 (da) * 2014-07-23 2021-10-18 Nat Ct Nanoscience & Technology China Polypeptid og polypeptidkompleks til undertrykkelse af tumormetastase og behandling af leukæmi samt fremgangsmåde til fremstilling deraf og anvendelse deraf
CA2990640A1 (en) * 2015-06-30 2017-01-05 Northwest Biotherapeutics, Inc. Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
KR20180044430A (ko) * 2015-09-15 2018-05-02 노쓰웨스트 바이오써라퓨틱스, 인크. 진행성 암을 가진 대상체를 위한 활성화된 수지상 세포 조성물 및 면역요법적 치료와 관련된 방법
CN105483084A (zh) * 2016-01-04 2016-04-13 英普乐孚生物技术(上海)有限公司 肿瘤抗原靶向性dc细胞的制备方法
WO2019246111A1 (en) 2018-06-19 2019-12-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
IL286907B2 (en) * 2019-04-03 2025-11-01 Akron Bioproducts Llc Cryopreservation and cell culture media
CA3148229A1 (en) * 2019-07-12 2021-01-21 Kyushu University, National University Corporation Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death
US20220401535A1 (en) * 2019-11-18 2022-12-22 Children's Medical Center Corporation Hyperactive Dendritic Cells Enable Durable Adoptive Cell Transfer-Based Anti-Tumor Immunity
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
JP7652461B2 (ja) * 2021-05-07 2025-03-27 ナノファエンテック カンパニー リミテッド 樹状細胞の培養方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
US12584107B2 (en) * 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
US20230288400A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
CN118389430A (zh) * 2024-04-12 2024-07-26 广东壹加再生医学研究院有限公司 一种高抗肿瘤特异性dc-cik细胞的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72829T1 (de) * 1985-06-11 1992-03-15 Us Commerce In einem serumfreien medium in suspension kultivierte humane monozyten.
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
JP3649335B2 (ja) 1992-04-01 2005-05-18 ザ ロックフェラー ユニバーシティー 樹枝状細胞前駆体のインビトロ増殖の方法およびその免疫原製造への使用
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
PT2322603T (pt) * 2001-09-06 2020-01-21 Northwest Biotherapeutics Inc Composições e métodos para ativaçao linfocitária de células dendríticas monocíticas e células para resposta th-1
DK2298436T3 (da) 2002-06-19 2014-11-10 Northwest Biotherapeutics Inc Brug af en tangentiel flowfiltreringsenhed og metoder til leukocytberigelse
BRPI0407002A (pt) * 2003-02-10 2006-01-10 Northwest Biotherapeutics Inc Células cultivadas que apresentam antìgeno cd14+

Also Published As

Publication number Publication date
US20210102169A1 (en) 2021-04-08
IL170512A (en) 2013-12-31
EP1604016B1 (de) 2009-01-14
EP1604016A2 (de) 2005-12-14
HK1086597A1 (en) 2006-09-22
MXPA05009178A (es) 2006-03-08
US20160024472A1 (en) 2016-01-28
WO2004076651A3 (en) 2005-03-10
RU2364625C2 (ru) 2009-08-20
US10731130B2 (en) 2020-08-04
NZ542071A (en) 2007-11-30
JP4762887B2 (ja) 2011-08-31
KR20050107471A (ko) 2005-11-11
JP2006519021A (ja) 2006-08-24
US8389278B2 (en) 2013-03-05
US11827903B2 (en) 2023-11-28
RU2005129561A (ru) 2006-03-10
PL378291A1 (pl) 2006-03-20
DE602004019057D1 (de) 2009-03-05
KR101201875B1 (ko) 2012-11-15
TW200506061A (en) 2005-02-16
CN1784488A (zh) 2006-06-07
AU2010201319A1 (en) 2010-04-29
ES2321939T3 (es) 2009-06-15
US9102917B2 (en) 2015-08-11
PL209998B1 (pl) 2011-11-30
US20130273654A1 (en) 2013-10-17
CN1784488B (zh) 2010-07-28
AU2010201319B2 (en) 2012-09-06
BRPI0407900A (pt) 2006-03-21
DK1604016T3 (da) 2009-05-18
CA2517295C (en) 2016-01-12
WO2004076651A2 (en) 2004-09-10
US20040203143A1 (en) 2004-10-14
AU2004214896A1 (en) 2004-09-10
KR20110106474A (ko) 2011-09-28
CA2517295A1 (en) 2004-09-10
EP1604016A4 (de) 2006-03-08
CY1109099T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
ATE420946T1 (de) Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine
Peters et al. Signals required for differentiating dendritic cells from human monocytes in vitro
Santini et al. The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity
Lu et al. Th9 cells promote antitumor immune responses in vivo
Kadowaki Dendritic cells—a conductor of T cell differentiation—
Santini et al. A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells
Jongmans et al. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails
Chen et al. Follicular helper T cells promote liver pathology in mice during Schistosoma japonicum infection
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
JP2008535493A5 (de)
Gregori Dendritic cells in networks of immunological tolerance
ATE525908T1 (de) Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
EP2626415A3 (de) Verfahren zur Erweiterung von Myeloidzellpopulationen und Verwendungen dafür
CN116004533B (zh) iNKT细胞的激活扩增方法及其培养基组合
Lee IV et al. Inhibition of CD4+ CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine
Jegatheeswaran et al. Searching for the elusive regulatory innate lymphoid cell
DE60108661D1 (de) Herstellung und verwendung von dendritischen zellen
Lim et al. Principal role of IL-12p40 in the decreased Th1 and Th17 responses driven by dendritic cells of mice lacking IL-12 and IL-18
AR128929A1 (es) Composiciones y métodos para activar células inmunitarias
Trujillo-Ocampo et al. IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA-CD62L+ CD4+ Invariant NKT Cells With Th-2 Biased Cytokine Production Profile
DE60229960D1 (de) Herstellung kultivierter menschlicher mastzellen und basophilen zur hochdurchsatz-entdeckung kleiner arzneistoffmoleküle
Pizzurro et al. Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine
O'Connell et al. Type‐1 polarized nature of mouse liver CD8α–and CD8α+ dendritic cells: tissue‐dependent differences offset CD8α‐related dendritic cell heterogeneity
ATE371722T1 (de) Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen
Baumeister et al. G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties